BRAND-EMBASSY
Digital customer service platform, Brand Embassy , has agreed a partnership with global technology and CRM specialists, Avaya , in order to better address a major shift to digital customer interactions in Europe.
The partnership was announced at the Avaya Forum 2016, which took place in Prague in September, by Brand Embassy CEO, Vit Horky, and Avaya Global Account Manager, Patrik Monari.
“10 years ago there was no web chat, smartphone apps, social media, and very little email. Today, digital interactions account for over 35% of all customer service interactions and, at the current rate, will overtake voice in two years’ time. We approached Brand Embassy, a recognised leader in the digital customer care segment, to augment our offering for our largest customers in the European region,” states Patrik Monari, Avaya Global Account Manager
“People use mobile apps and connect with brands on facebook every single day. Done right, Omnichannel customer service can result in higher customer satisfaction, more efficient employees, accelerated response and higher conversion rates. Avaya is a global leader in technology and CRM software, and we’re delighted to commence such a mission-critical cooperation with them,” states Vit Horky , Brand Embassy Founder & CEO
Brand Embassy, whose development team is based in Prague, Czech Republic, is cooperating with Avaya to deliver a truly omnichannel experience in customer service for Enterprise and high-growth customers, mainly from the telco, banking and eCommerce sectors.
Notes to Editors
About Brand Embassy
The top-rated social customer service platform, Brand Embassy , helps companies acquire and retain customers through digital customer service at scale. Our clients are major Enterprises and high-growth companies from the telco, banking and eCommerce sectors, such as: T-Mobile, Telenor, Telefonica, Vodafone, Home Credit, Societe Generale, GE Money, Samsung, Mall.cz, Zoot. Brand Embassy is headquartered in London, with offices in Prague and San Francisco. See more, here
About Avaya
Avaya Inc . is an American multinational technology company headquartered in Santa Clara, California that specializes in Internet telephony, wireless data communications, and Customer relationship management (CRM) software, and provides business communication solutions for customer and team engagement. Avaya currently services organizations at over 1 million customer locations worldwide with operations divided globally in 5 regions. See more, here
View source version on businesswire.com: http://www.businesswire.com/news/home/20161006005066/en/
Contact:
Brand Embassy
Brendan Donnellan
Marketing Director
+420734819716
Brendan.donnellan@brandembassy.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release
Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom